Figures & data
Table 1. Naloxone distribution model parameters.
Table 2. Key epidemiologic parameters for model calibration.
Table 3. Sensitivity analyses.
Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158:1-9 Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 2010;21:186-93 Sergeev B, Karpets A, Sarang A, et al. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. J Urban Health 2003;80:212-9 Davidson PJ, McLean RL, Kral AH, et al. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health 2003;80:261-73 Davidson PJ, Ochoa KC, Hahn JA, et al. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction 2002;97:1511-6 Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction 1996;91:405-11 Coffin PO. Overdose: a major cause of preventable death in central and Eastern Europe in Central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Vilnius, Lithuania: Eurasian Harm Reduction Network, 2008 Bohnert AS, Tracy M, Galea S. Characteristics of drug users who witness many overdoses: implications for overdose prevention. Drug Alcohol Depend 2012;120:168-73 Coffin PO. Overdose and femoral injection among Seattle-area injection drug users. In: National Institute on Drug Abuse, ed. Epidemiologic trends in drug abuse. Proceedings of the Community Epidemiology Work Group. Rockville, MD, June 2011 Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130:584-90 Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 2007;49:172-7 Grau LE, Green TC, Torban M, et al. Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduct J 2009;6:17-28 Wampler DA, Molina DK, McManus J, et al. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 2011;15:320-4 Doe-Simkins M, Walley AY, Epstein A, et al. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788-91 Piper TM, Stancliff S, Rudenstine S, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse 2008;43:858-70 Stoove MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev 2009;28:347-52 Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 2008;103:1648-57 Tobin KE, Sherman SG, Beilenson P, et al. Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy 2009;20:131-6 Coffin PO, Tracy M, Bucciarelli A, et al. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007;14:616-23 Darke S, Williamson A, Ross J, et al. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J Urban Health 2007;84:283-91 Darke S, Mills KL, Ross J, et al. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001–2009. Drug Alcohol Depend 2011;115:190-5 Teesson M, Mills K, Ross J, et al. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008;103:80-8 Huo D, Bailey SL, Ouellet LJ. Cessation of injection drug use and change in injection frequency: the Chicago Needle Exchange Evaluation Study. Addiction 2006;101:1606-13 Bruneau J, Brogly SB, Tyndall MW, et al. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction 2004;99:727-37 Open Health Institute. Harm reduction programs in the civilian and prison sectors of the Russian Federation: assessment of best practices. Moscow: World Bank, 2006 Musatov VA. Abstinence from drugs vs reducing harm. Sixth School for Journalists Writing on Health Issues. Pushkino School for Journalism: Pushkino, Russia, 2006 Hser YI. Drug use careers: recovery and mortality. In Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Substance use by older adults: estimates of future impact on the treatment system. OAS Analytic Series #A-21, DHHS Publication No. (SMA) 03-3763. Rockville, MD: SAMHSA 2002 Evans JL, Hahn JA, Lum PJ, et al. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend 2009;101:152-7 Tufts G. Return of the ambulance. Moscow, Russia: Rossijskaya Gazeta, 2011 Russian Federation Ministry of Health and Social Development. Health/Medical Insurance; Information Letter on the formation and economic justification of territorial programs providing government guarantees for free healthcare for Russian citizens in 2011. Moscow, Russia: Russian Federation Ministry of Health and Social Development; 2012 United States Agency for International Development. Russia: HIV/AIDS Health Profile. Moscow, Russia: USAID/Russia; 2010. p 4 Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS, 2010 Krupitsky EM, Zvartau EE, Lioznov DA, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addict Res 2006;12:12-19 World Health Organization. Global Tuberculosis Control: Russian Federation Country Profile. Geneva: World Health Organization, 2011 Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90:1100-11 Nosyk B, Sun H, Guh DP, et al. The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol 2010;63:1132-44 Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone maintenance treatment in Lithuania. Medicina (Kaunas) 2010;46:286-92 Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103:979-89 Mackesy-Amiti ME, Ouellet LJ, Golub ET, et al. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction 2011;106:601-8 Sherman SG, Gann DS, Scott G, et al. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J 2008;5:2-6 Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006;101:1499-508 Green TC, Grau LE, Blinnikova KN, et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy 2009;20:270-6